16
total announcements
SHUKRAPHAR.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 04 Oct 2026
Market Cap
₹2,733 Cr
P/E (TTM)
79.5
EPS (TTM)
₹0.78
52W Low
₹40.06
52W High
₹65.40
Dividend Yield
0.02%
Beta
0.57
Price / Book
29.6
Debt / Equity
5.6
Revenue (TTM)
₹75 Cr
Gross Margin
81.91%
Operating Margin
79.08%
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizers report of Postal Ballot. The company has informed the Exchange regarding voting results of the resolutions passed in the meeting.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 28, 2026. The 33rd Annual General Meeting (AGM) of the Company was held through video conferencing, in compliance with the applicable provisions of the Companies Act, 2013, and SEBI circulars.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has announced the record date for determining the eligibility of members to receive the final dividend for the financial year ended 31 March 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026, to consider and adopt audited financial statements for the financial year ended March 31, 2026, approve and declare final dividend, re-appoint a director, and regularize the appointment of an additional independent director.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has rescheduled its 33rd Annual General Meeting (AGM) to September 28, 2026, due to unavoidable administrative exigencies. The revised book closure dates are September 22-28, 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, specifically the Record Date for determining eligibility for Final Dividend for the financial year ended 31 March, 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 02, 2026, where the Board of Directors approved allotment of 11,73,000 fully paid-up equity shares to Navkar Surgical Gujarat Limited, warrant holders (Promoter), upon conversion of warrants into equity shares.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about the completion of dispatch of the postal Ballot Notice as published in Business Standard (English) and in Jai Hind (Gujarati) on August 31, 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot for approval of special businesses through e-voting process.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 22, 2026. The Board of Directors considered and approved several items, including the change of the company's name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited', alteration in the main objects of the Company, and consequential alteration in the Main Object Clause of the Memorandum of Association. The company also approved the draft notice of Postal Ballot to obtain shareholders' approval for the aforesaid relevant agenda items and appointed CS Rupal Patel as a Scrutinizer to scrutinize the e-voting process.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates regarding media coverage of its NSE listing and strategic direction.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, including approval of proposal for change of name and expansion of main objects to include medical technology.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, specifically the commencement of trading of its equity shares on the National Stock Exchange of India Limited (NSE) with effect from August 14, 2026.
Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has announced its direct listing on the National Stock Exchange (NSE) and will commence trading on August 14, 2026. The company will continue to trade on the Bombay Stock Exchange (BSE) as well. The listing is aimed at expanding the company's visibility, attracting a broader base of institutional and retail investors, and deepening market liquidity.